Search Results for "Takeda"

19:36 EDT 22nd August 2014 | BioPortfolio

Original Source: Takeda Global Research & Development Center, Inc.

Takeda Global Research & Development Center, Inc. (TGRD) is a company focused on becoming an integrated, global, world-class pharmaceutical development organization with the ability to rapidly bring superior products to market to improve patient health and enhance the practice of medicine. Established in January 2004, TGRD integrates the clinical development activity of the Takeda Pharmaceutical North America, Inc. (TPNA) R&D group and Takeda's European R&D operation, Takeda Europe Research & Development Ce...

Matching Channels

Pertussis Vaccine acellular Takeda

Actos

Actos, produced by Takeda Pharmaceuticals North America, Inc netted $2.5m in sales in 2009, the 9th highest in the world. Actos is a type of thiazolidinediones, acting to increase sensitivity to I...

Prevacid

Prevacid, produced by Takeda Pharmaceuticals North America, Inc netted $2.5 in sales in 2009, the 10th highest in the world. Prevacid, the trade name for lansoprazole, is a proton pump inhibitor d...

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

Matching News

Jury Finds for Takeda in Diabetes Drug Case Takeda Emphasizes Continued Commitment to Actos and Patient Safety

Deerfield, Ill., May 15, 2014, and Osaka, Japan, May 16, 2014 – Takeda Pharmaceutical Company Limited (“Takeda”) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc....

New Takeda CFO Takes Takeda Investor Search Abroad As Firm Goes Global

The recent influx of foreign executives at Takeda Pharmaceutical has led to a broadening of the firm's shareholder base to beyond its shores.

Jury finds in favor of Takeda in diabetes drug Actos case

The US subsidiary of Japan’s largest drugmaker, Takeda Pharmaceuticals, yesterday announced that in the case of Bertha Triana and Delores Cipriano v Takeda, et al, No. A680556 the jury found in favo...

Takeda ends Affymax deal, to pull Omontys NDA

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is ending a 2006 deal with Affymax Inc. (OTCQB:AFFY) to co-develop and co-commercialize Omontys peginesatide, effective Sept. 10. The pharma said it also wi...

Takeda Recognized as a Nadeshiko Brand, An Enterprise Encouraging Women's Success in the Workplace

Osaka, Japan, March 4, 2014 –Takeda Pharmaceutical Company Limited (Takeda) announced today that the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) have recogn...

Takeda Announces the New Drug Application Approval of Cell Cultured Influenza vaccine H5N1 "TAKEDA" 1mL and Cell Cultured Influenza vaccine (Prototype) "TAKEDA" 1mL in Japan for Prevention of Pandemic Influenza

Osaka, Japan, March 31, 2014 – Takeda Pharmaceutical Company Limited (“Takeda”) announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the New D...

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion agreement in Japan for TAK-438 (vonoprazan fumarate), a drug discovered by Takeda for the treatment...

Otsuka, Takeda partner to co-promote gastrointestinal drug TAK-438 in Japan

Japanese firms Otsuka Pharmaceutical (Otsuka) and Takeda Pharmaceutical (Takeda) have signed an agreement for the future co-promotion of sales in Japan of TAK-438 (Vonoprazan Fumarate) for the treatme...

Matching PubMed Articles

Laparoscopic Removal of a Congenital Seminal Vesicle Cyst in Zinner's Syndrome.

Seminal vesicle cysts are rarely diagnosed, but symptomatic congenital seminal vesicle cysts are reported in the literature describing Zinner syndrome. Case Description: We present the case of a 26-ye...

Vortioxetine for the treatment of major depression.

Vortioxetine (Lu-AA-21004; 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine hydrobromide) is a novel orally active molecule that is being investigated by Lundbeck and Takeda for the treatment of maj...

World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.

The World Antibody-Drug Conjugate (WADC) Summits organized by Hanson Wade are currently the largest meetings fully dedicated to ADCs. The first global ADC Summit was organized in Boston in October 201...

Nucleophilic cross-linked, dextran coated iron oxide nanoparticles as basis for molecular imaging: synthesis, characterization, visualization and comparison with previous product.

We present a new synthesis protocol for a multivalent, multimodality, nucleophilic nanoparticle ideal for in vivo imaging. Stability requirements necessitated covalent cross-linking of the carbohydrat...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement